Literature DB >> 11012329

Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma.

S V Rajkumar, M A Gertz, T E Witzig.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11012329     DOI： 10.1056/NEJM200009283431315

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

2.  Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.

Authors:  Pascale Olivier-Abbal; Anne-Charlotte Teisseyre; Jean-Louis Montastruc
Journal:  Med Oncol       Date:  2013-09-28       Impact factor: 3.064

Review 3.  Management of thalidomide toxicity.

Authors:  Irene M Ghobrial; S Vincent Rajkumar
Journal:  J Support Oncol       Date:  2003 Sep-Oct

4.  Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.

Authors:  Marianna Colagrande; Mauro Di Ianni; Gino Coletti; Ketty Peris; Maria Concetta Fargnoli; Lorenzo Moretti; Mario Lapecorella; Antonio Tabilio
Journal:  Int J Hematol       Date:  2008-12-04       Impact factor: 2.490

Review 5.  Therapy strategies for multiple myeloma: current status.

Authors:  Heinz Gisslinger; Mathias Kees
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

6.  Life-threatening dermatologic adverse events in oncology.

Authors:  Alyx C Rosen; Yevgeniy Balagula; Dennis W Raisch; Vishvas Garg; Beatrice Nardone; Nicole Larsen; Jennifer Sorrell; Dennis P West; Milan J Anadkat; Mario E Lacouture
Journal:  Anticancer Drugs       Date:  2014-02       Impact factor: 2.248

7.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 8.  Breakthroughs in the management of multiple myeloma.

Authors:  Leonard T Heffner; Sagar Lonial
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.

Authors:  T E Clark; N Edom; J Larson; L J Lindsey
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 10.  Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.

Authors:  Chau Yee Ng; Chun-Bing Chen; Ming-Ying Wu; Jennifer Wu; Chih-Hsun Yang; Rosaline Chung-Yee Hui; Ya-Ching Chang; Chun-Wei Lu
Journal:  J Immunol Res       Date:  2018-01-17       Impact factor: 4.818
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.